ReP USP - Resultado da busca

Filtros : "Financiamento MCTI" "LOUZADA JÚNIOR, PAULO" Removido: "APRENDIZADO COMPUTACIONAL" Limpar

Filtros

Autores USP
- fonseca, benedito antonio lopes da (~2)
- kallas, esper georges (~2)
- louzada júnior, paulo (~2)
- rodrigues, fernando bellissimo (~2)
Ano de publicação
- 2023 (~1)
- 2021 (~1)
Assuntos
- covid-19 (2)
- pacientes internados (2)
- brasil (1)
- citocinas (1)
- ensaio clínico controlado randomizado (1)

Artigo de periodico
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) (2023)
Bonifácio, Lívia Pimenta ; Ramacciotti, Eduardo ; Agati, Leandro Barile ; Vilar, Fernando Crivelenti; Silva, Anna Christina Tojal da; Louzada Junior, Paulo; Fonseca, Benedito Antonio Lopes da; Souza, Hayala Cristina Cavenague de; Oliveira, Caroline Candida Carvalho de; Aguiar, Valeria Cristina Resende; Kallas, Esper Georges ; Rodrigues, Fernando Bellíssimo
Fonte: Revista da sociedade brasileira de medicina tropical. Unidades: FMRP, FM
Assuntos: COVID-19, PACIENTES INTERNADOS, PANDEMIAS, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONIFÁCIO, Lívia Pimenta et al. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, v. 56, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54695. Acesso em: 04 nov. 2025.
APA
Bonifácio, L. P., Ramacciotti, E., Agati, L. B., Vilar, F. C., Silva, A. C. T. da, Louzada Junior, P., et al. (2023). Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, 56. doi:10.1590/0037-8682-0565-2022
NLM
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2025 nov. 04 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695
Vancouver
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2025 nov. 04 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695
Trabalho de evento-resumo periodico
Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) (2021)
Bonifacio, L.; Ramacciotti, E.; Agati, L.; Vilar, F.; Tojal, A.; Souza, H.; Louzada Júnior, Paulo; Fonseca, Benedito Antonio Lopes da; Lopes, R.; Kallas, Esper Georges ; Bellíssimo-Rodrigues, Fernando
Fonte: Antimicrobial Resistance & Infection Control. Nome do evento: International Conference on Prevention & Infection Control (ICPIC 2021). Unidades: FMRP, FM
Assuntos: COVID-19, PACIENTES INTERNADOS, ESTUDOS MULTICÊNTRICOS, ESTUDOS PROSPECTIVOS, CITOCINAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONIFACIO, L. et al. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf. Acesso em: 04 nov. 2025. , 2021
APA
Bonifacio, L., Ramacciotti, E., Agati, L., Vilar, F., Tojal, A., Souza, H., et al. (2021). Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Recuperado de https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf
NLM
Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2025 nov. 04 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf
Vancouver
Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2025 nov. 04 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo 2012 - 2025